Literature DB >> 21919994

Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia--a propensity-adjusted analysis.

G Choudhury1, P Mandal, A Singanayagam, A R Akram, J D Chalmers, A T Hill.   

Abstract

There are no studies to guide the optimal duration of therapy in severe community-acquired pneumonia (CAP). The aim of this study was to determine whether 7 days of antibiotic treatment is equivalent to longer-course therapy in severe CAP. In this prospective observational study, we included patients with severe CAP (CURB65 score 3-5) admitted to the hospital with signs and symptoms consistent with pneumonia. A propensity score, derived through multiple logistic regression, was used to match patients into two groups: treated for 7 days vs. treated for >7 days. Patients who died, were admitted to the intensive-care unit, developed complicated pneumonia, failed to reach clinical stability or had positive cultures for microorganisms requiring prolonged treatment within the first 7 days were excluded. Patients outside the mutual range of the propensity score were also excluded. The primary outcome of this study was 30-day mortality. Secondary outcomes were subsequent requirement for mechanical ventilation and/or inotropic support and the development of complicated pneumonia or re-admission within 30 days. Four hundred and twelve patients were suitable for derivation of the propensity score. After matching on propensity score, 164 patients treated for 7 days were compared with 164 treated for >7 days; they were well matched in terms of age, gender, comorbidities, and physiological parameters. The results showed no significant differences in the primary and the secondary outcomes between the two groups. This study therefore suggests that, in the majority of severe CAP patients who have clinically responded, antibiotics can be safely discontinued at 7 days.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21919994     DOI: 10.1111/j.1469-0691.2011.03542.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  10 in total

1.  Addendum to: Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study.

Authors:  Daniel R Morales; Rob Flynn; Xavier Kurz
Journal:  Clin Drug Investig       Date:  2019-06       Impact factor: 2.859

2.  Determining the duration of therapy for patients with community-acquired pneumonia.

Authors:  Nikole M Scalera; Thomas M File
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725

3.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.

Authors:  Andrew Rhodes; Laura E Evans; Waleed Alhazzani; Mitchell M Levy; Massimo Antonelli; Ricard Ferrer; Anand Kumar; Jonathan E Sevransky; Charles L Sprung; Mark E Nunnally; Bram Rochwerg; Gordon D Rubenfeld; Derek C Angus; Djillali Annane; Richard J Beale; Geoffrey J Bellinghan; Gordon R Bernard; Jean-Daniel Chiche; Craig Coopersmith; Daniel P De Backer; Craig J French; Seitaro Fujishima; Herwig Gerlach; Jorge Luis Hidalgo; Steven M Hollenberg; Alan E Jones; Dilip R Karnad; Ruth M Kleinpell; Younsuk Koh; Thiago Costa Lisboa; Flavia R Machado; John J Marini; John C Marshall; John E Mazuski; Lauralyn A McIntyre; Anthony S McLean; Sangeeta Mehta; Rui P Moreno; John Myburgh; Paolo Navalesi; Osamu Nishida; Tiffany M Osborn; Anders Perner; Colleen M Plunkett; Marco Ranieri; Christa A Schorr; Maureen A Seckel; Christopher W Seymour; Lisa Shieh; Khalid A Shukri; Steven Q Simpson; Mervyn Singer; B Taylor Thompson; Sean R Townsend; Thomas Van der Poll; Jean-Louis Vincent; W Joost Wiersinga; Janice L Zimmerman; R Phillip Dellinger
Journal:  Intensive Care Med       Date:  2017-01-18       Impact factor: 17.440

4.  Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.

Authors:  Laura Evans; Andrew Rhodes; Waleed Alhazzani; Massimo Antonelli; Craig M Coopersmith; Craig French; Flávia R Machado; Lauralyn Mcintyre; Marlies Ostermann; Hallie C Prescott; Christa Schorr; Steven Simpson; W Joost Wiersinga; Fayez Alshamsi; Derek C Angus; Yaseen Arabi; Luciano Azevedo; Richard Beale; Gregory Beilman; Emilie Belley-Cote; Lisa Burry; Maurizio Cecconi; John Centofanti; Angel Coz Yataco; Jan De Waele; R Phillip Dellinger; Kent Doi; Bin Du; Elisa Estenssoro; Ricard Ferrer; Charles Gomersall; Carol Hodgson; Morten Hylander Møller; Theodore Iwashyna; Shevin Jacob; Ruth Kleinpell; Michael Klompas; Younsuck Koh; Anand Kumar; Arthur Kwizera; Suzana Lobo; Henry Masur; Steven McGloughlin; Sangeeta Mehta; Yatin Mehta; Mervyn Mer; Mark Nunnally; Simon Oczkowski; Tiffany Osborn; Elizabeth Papathanassoglou; Anders Perner; Michael Puskarich; Jason Roberts; William Schweickert; Maureen Seckel; Jonathan Sevransky; Charles L Sprung; Tobias Welte; Janice Zimmerman; Mitchell Levy
Journal:  Intensive Care Med       Date:  2021-10-02       Impact factor: 17.440

Review 5.  Antimicrobial Treatment Duration in Sepsis and Serious Infections.

Authors:  Lindsay M Busch; Sameer S Kadri
Journal:  J Infect Dis       Date:  2020-07-21       Impact factor: 5.226

6.  Oral versus intravenous clarithromycin in moderate to severe community-acquired pneumonia: an observational study.

Authors:  Nikolas Rae; Aran Singanayagam; Stuart Schembri; James D Chalmers
Journal:  Pneumonia (Nathan)       Date:  2017-02-05

Review 7.  Community-acquired pneumonia.

Authors:  Elena Prina; Otavio T Ranzani; Antoni Torres
Journal:  Lancet       Date:  2015-08-12       Impact factor: 79.321

8.  Multi-Modal Data Analysis for Pneumonia Status Prediction Using Deep Learning (MDA-PSP).

Authors:  Ruey-Kai Sheu; Lun-Chi Chen; Chieh-Liang Wu; Mayuresh Sunil Pardeshi; Kai-Chih Pai; Chien-Chung Huang; Chia-Yu Chen; Wei-Cheng Chen
Journal:  Diagnostics (Basel)       Date:  2022-07-13

9.  Predicting and managing sepsis in burn patients: current perspectives.

Authors:  Omar Nunez Lopez; Janos Cambiaso-Daniel; Ludwik K Branski; William B Norbury; David N Herndon
Journal:  Ther Clin Risk Manag       Date:  2017-08-29       Impact factor: 2.423

10.  Irradiation enhanced risks of hospitalised pneumonopathy in lung cancer patients: a population-based surgical cohort study.

Authors:  Shih-Kai Hung; Yi-Chun Chen; Wen-Yen Chiou; Chun-Liang Lai; Moon-Sing Lee; Yuan-Chen Lo; Liang-Cheng Chen; Li-Wen Huang; Nai-Chuan Chien; Szu-Chi Li; Dai-Wei Liu; Feng-Chun Hsu; Shiang-Jiun Tsai; Michael Wy Chan; Hon-Yi Lin
Journal:  BMJ Open       Date:  2017-09-27       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.